Ascendis Pharma A/S (ASND) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.90
- Estimate
- $0.77
- Surprise
- +17.4%
- Score at report (before → after)
- 6.1 → 6.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Ascendis Pharma A/S (ASND) beat the $0.77 estimate with adjusted EPS of $0.90 — a large 17.4% upside surprise. TrendMatrix's engine moved from Sell (6.1/10) to Hold at 6.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ASND Hold at 6.9/10.
1 of the last 4 quarters beat the estimate; this quarter's +17.4% surprise compares with a -145.1% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Thin upside margin: 9.7%
- Consecutive earnings misses (2)
- Overbought (RSI 83)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $250.17
- Price target
- $274.45
- Stop
- $239.29
- Upside to target
- +9.7%
- Reward-to-risk
- 0.8:1
Forward estimates sit below the trailing run-rate (24.9× forward vs 19.1× trailing) — consensus expects earnings to decline from here.
Risk check: RSI 83 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
ASND at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $16.38B
- P/E (fwd)
- 24.9
- P/E (ttm)
- 19.1
- 52-week range
- $188.07–$282.15
- Off 52-week high
- 11.3%
- RSI (14)
- 83
- Volume vs avg
- 0.94×
- Score today
- 6.9/10